Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT04720976
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 280
- Registration Number
- NCT04676477
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 272
- Registration Number
- NCT04575415
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 18
- Registration Number
- NCT04545710
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Genprex, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT04486833
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Carle Cancer Institute, Urbana, Illinois, United States
🇺🇸Millennium Oncology, Houston, Texas, United States
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1074
- Registration Number
- NCT04487080
- Locations
- 🇯🇵
National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-shi, Japan
🇯🇵National Cancer Center Hospital, Chuo Ku, Japan
🇯🇵Wakayama Medical University Hospital, Wakayama, Japan
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT04479306
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-11
- Target Recruit Count
- 20
- Registration Number
- NCT04425681
- Locations
- 🇨🇳
The Second Afiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Michael Hopp
- Target Recruit Count
- 34
- Registration Number
- NCT04413201
- Locations
- 🇩🇪
Sana-Klinikum Offenbach, Offenbach, Hessen, Germany
🇩🇪Klinikum Bremen-Ost, Bremen, Germany
🇩🇪Gemeinnützige Krankenhausbetriebsgesellschaft Konstanz Mbh, Konstanz, Germany
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 571
- Registration Number
- NCT04410796
- Locations
- 🇺🇸
University of Washington (Data Collection Only), Seattle, Washington, United States
🇺🇸UC Davis Cancer Center (Data Collection Only), Sacramento, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.